Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | MYC | P01106 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9587397 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL9587118 | 0.79 | CASP1 (0.56) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL7358766 | 0.76 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL11812265 | 0.70 | DHODH (0.44) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL11808817 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL11814853 | 0.69 | ALDH1A1 (0.44) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL17843998 | 0.68 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL4579109 | 0.68 | GAA (0.58) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL30168361 | 0.68 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL9586863 | 0.68 | MAPT (0.47) | SMN1; SMN2MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943610-B2 | Pyrazolopyridine-1,4-diamines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943610-B2 | Pyrazolopyridine-1,4-diamines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1869043-A2 | PYRAZOLOPYRIDINE-1,4-DIAMINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107853-A2 | PYRAZOLOPYRIDINE-1,4-DIAMINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | IL4, IL2, IL1A | SMN1; SMN2 3551/4885MEN1 2626/4885KMT2A 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.